Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin
- 1 February 2008
- journal article
- research article
- Published by Elsevier in Genetics in Medicine
- Vol. 10 (2), 139-150
- https://doi.org/10.1097/gim.0b013e318163c35f
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- A Rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleedingGenetics in Medicine, 2008
- A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistanceBlood, 2006
- Translating the Results of Randomized Trials into Clinical PracticeStroke, 2006
- CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet™ systematic review and meta-analysisGenetics in Medicine, 2005
- Antithrombotic Therapy for Venous Thromboembolic DiseaseChest, 2004
- Antithrombotic and Thrombolytic Therapy for Ischemic StrokeChest, 2004
- Antithrombotic Therapy for Coronary Artery DiseaseChest, 2004
- Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2Nature, 2004
- Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factorsThe Pharmacogenomics Journal, 2003
- Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin TherapyJAMA, 2002